These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12893983)

  • 1. Prediction of successful weight reduction under sibutramine therapy through genotyping of the G-protein beta3 subunit gene (GNB3) C825T polymorphism.
    Hauner H; Meier M; Jöckel KH; Frey UH; Siffert W
    Pharmacogenetics; 2003 Aug; 13(8):453-9. PubMed ID: 12893983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight loss and body fat reduction under sibutramine therapy in obesity with the C825T polymorphism in the GNB3 gene.
    Hsiao DJ; Wu LS; Huang SY; Lin E
    Pharmacogenet Genomics; 2009 Sep; 19(9):730-3. PubMed ID: 19687782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of successful weight reduction under sibutramine therapy.
    Sahelijo L; Katz DA; Spear BB
    Pharmacogenetics; 2004 Jun; 14(6):387; author reply 387-9. PubMed ID: 15247631
    [No Abstract]   [Full Text] [Related]  

  • 4. A controlled pharmacogenetic trial of sibutramine on weight loss and body composition in obese or overweight adults.
    Grudell AB; Sweetser S; Camilleri M; Eckert DJ; Vazquez-Roque MI; Carlson PJ; Burton DD; Braddock AE; Clark MM; Graszer KM; Kalsy SA; Zinsmeister AR
    Gastroenterology; 2008 Oct; 135(4):1142-54. PubMed ID: 18725220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.
    Vazquez Roque MI; Camilleri M; Clark MM; Tepoel DA; Jensen MD; Graszer KM; Kalsy SA; Burton DD; Baxter KL; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):829-37. PubMed ID: 17544870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term weight loss with sibutramine: a randomized controlled trial.
    Wirth A; Krause J
    JAMA; 2001 Sep; 286(11):1331-9. PubMed ID: 11560538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
    Smith IG; Goulder MA;
    J Fam Pract; 2001 Jun; 50(6):505-12. PubMed ID: 11407998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the common -866G/A polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population.
    Hsiao TJ; Wu LS; Hwang Y; Huang SY; Lin E
    Mol Diagn Ther; 2010 Apr; 14(2):101-6. PubMed ID: 20359253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A benefit-risk assessment of sibutramine in the management of obesity.
    Nisoli E; Carruba MO
    Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE; Ruiz AM; Monsalve MC; Berber A
    Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL; Apovian CM; Aronne LJ; Fernstrom MH; Frank A; Greenway FL; Heber D; Kushner RF; Cwik KM; Walch JK; Hewkin AC; Blakesley V
    Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.
    Zannad F; Gille B; Grentzinger A; Bruntz JF; Hammadi M; Boivin JM; Hanotin C; Igau B; Drouin P
    Am Heart J; 2002 Sep; 144(3):508-15. PubMed ID: 12228789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.
    James WP; Astrup A; Finer N; Hilsted J; Kopelman P; Rössner S; Saris WH; Van Gaal LF
    Lancet; 2000 Dec 23-30; 356(9248):2119-25. PubMed ID: 11191537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy.
    Serrano-Rios M; Melchionda N; Moreno-Carretero E;
    Diabet Med; 2002 Feb; 19(2):119-24. PubMed ID: 11874427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity.
    Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
    Int J Obes Relat Metab Disord; 2000 Feb; 24(2):144-50. PubMed ID: 10702763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sibutramine. A review of its contribution to the management of obesity.
    McNeely W; Goa KL
    Drugs; 1998 Dec; 56(6):1093-124. PubMed ID: 9878996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.